Who are Neuralymed's investors?

Neuralymed's investors include Octave Ventures Llc.

How much funding has Neuralymed raised?

Neuralymed has disclosed $10.5M raised across 2 rounds.

Where is Neuralymed headquartered?

Neuralymed is headquartered in Germantown, US.

Neuralymed

Germantown, US · Founded 2016 · Delaware corporation · 1 known investors

Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.

Biotech Healthtech

Founders & leadership

Neuralymed was founded in 2016 by Seulki Lee, Viktor Roschke, Ted Dawson, Martin Pomper, and Han Seok Ko.

Seulki LeeCEO

Viktor RoschkeCo-Founder, Advisor

Ted DawsonScientific Co-Founder, Advisor

Martin PomperScientific Co-Founder, Advisor

Han Seok KoScientific Co-Founder, Advisor

Investors · 1

Octave Ventures LlcHenderson

Reported raises · per SEC filings

Form D private placements

$10.5M disclosed across 2 rounds · 2016–2018

▶$10.4MraisedApr 2018 · 25 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Seulki LeeExecutive Officer, Director
Viktor RoschkeExecutive Officer, Director

Offering amount: $10.4M
Amount sold: $10.4M
First sale: Apr 2018
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$100KraisedDec 2016 · 2 investors · Other Health Care

Rule 506(b)

Officers, directors & promoters on the filing

Seulki LeeExecutive Officer

Offering amount: $1.5M
Amount sold: $100K
Minimum investment: $10K
First sale: Sep 2016
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Bioworld21 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Alnylam11 shared keywordsAlnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

Companies competing with Neuralymed for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Neuralymed do?: Neuraly is a clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative disorders, focusing on inhibiting pathological glial activation to prevent neuronal cell death. Its lead candidate NLY01 has been evaluated in Phase 2 trials for early Parkinson's disease.
Who founded Neuralymed?: Neuralymed was founded by Seulki Lee, Viktor Roschke, Ted Dawson, Martin Pomper, Han Seok Ko in 2016.
Who are Neuralymed's investors?: Neuralymed's investors include Octave Ventures Llc.
How much funding has Neuralymed raised?: Neuralymed has disclosed $10.5M raised across 2 rounds.
Where is Neuralymed headquartered?: Neuralymed is headquartered in Germantown, US.